您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > BTB06584
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BTB06584
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BTB06584图片
CAS NO:219793-45-0
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
BTB06584 (BTB-06584; BTB 06584) is a novel, potent and IF1-dependent inhibitor of the mitochondrial F1 Fo-ATPase, acting by selectively inhibiting mitochondrial F1 Fo-ATPase activity without compromising ATP synthesis and to limit ischaemia-induced injury caused by reversal of the mitochondrial F1 Fo-ATPsynthase.
理化性质和储存条件
Molecular Weight (MW)417.82
FormulaC19H12ClNO6S
CAS No.219793-45-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 84 mg/mL (201.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info

Chemical Name: 2-nitro-5-(phenylsulfonyl)phenyl 4-chlorobenzoate

InChi Key: WNDWKKPBLAKXMI-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H12ClNO6S/c20-14-8-6-13(7-9-14)19(22)27-18-12-16(10-11-17(18)21(23)24)28(25,26)15-4-2-1-3-5-15/h1-12H

SMILES Code: O=S(C1=CC(OC(C2=CC=C(Cl)C=C2)=O)=C([N+]([O-])=O)C=C1)(C3=CC=CC=C3)=O

SynonymsBTB06584; BTB 06584; BTB-06584
实验参考方法
In Vitro

In vitro activity: BTB06584 IF1-dependently inhibits F1 Fo-ATPase activity with no effect on without compromising ATP synthesis, and also limits ischemia-induced injury caused by reversal of the mitochondrial F1 Fo-ATP synthase.


Cell Assay: BTB inhibited F1Fo-ATPase activity with no effect on the mitochondrial membrane potential (ΔΨm) or O2 consumption. ATP consumption decreased via inhibition of respiration, and ischaemic cell death was reduced. BTB efficiency increased by IF1 overexpression and reduced by silencing this protein. In addition, BTB rescued defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the Atpif1a gene is lost.

In VivoBTB06584 rescues the defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants without causing significant toxicity.
Animal modelzebrafish pinotage
Formulation & DosageN/A
References

Br J Pharmacol. 2014 Sep;171(18):4193-206.